InsiderPulse
Dashboard

DXCM

DexCom, Inc.

Health CareS&P 500NASDAQ 100

DexCom, Inc. insider trading

DexCom, Inc. files with the SEC as a Surgical & Medical Instruments & Apparatus company headquartered in San Diego, CA. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.

From SEC filings

Recent DXCM insider transactions

8 insiders traded DXCM on the open market between Jun 03, 2026 and Sep 15, 2026 — 20 sales worth $9.6M, of which every one was pre-scheduled under a 10b5-1 plan.

Bought
—
Sold
$9.6M

20 of 20 on a 10b5-1 plan

Net
−$9.6M
Insiders
8

Open-market purchases (code P) and sales (code S) from DexCom, Inc.'s own SEC Form 4 filings. Grants and option exercises are excluded — they are compensation, not decisions. Share counts are derived from the reported value and price. Verify any figure against the original filing before acting on it; this is monitoring, not advice.

Filing history last read from EDGAR on Sep 21, 2026. The live dashboard shows new filings the moment they clear.

Every DXCM Form 4 on SEC.gov

SEC Form 4 data, Q3 2024 to Q2 2026

DXCM insider trading by quarter

Between Jul 01, 2024 and Jun 30, 2026, 12 insiders traded DXCM on the open market: 2 purchases worth $1M and 57 sales worth $18.5M, 40 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 2 purchases ($1M) and 24 sales ($5.2M), by 10 insiders.

QuarterBoughtSold
Q2 2026—−$3.3M9 sales · all on a plan
Q1 2026—−$179.1K2 sales · all on a plan
Q4 2025+$1M2 buys−$448.2K3 sales · all on a plan
Q3 2025—−$1.2M10 sales · all on a plan
Q2 2025—−$2.3M7 sales · all on a plan
Q1 2025—−$10M14 sales · 4 on a plan
Q4 2024—−$806.4K6 sales · 2 on a plan
Q3 2024—−$296K6 sales · 3 on a plan
Largest purchase
+$863.2K of DXCM by Leach Jacob Steven (President & COO) on Nov 10, 2025.
Largest sale
−$2.9M of DXCM by Sayer Kevin R (Chairman, CEO & President · Director) on Jan 29, 2025.

Open-market transactions through Jun 30, 2026most recent first

  • Foletta Mark G10b5-1

    Director

    −$281.7K

    Jun 15, 2026

    3,801 sh · $74.10

  • Sayer Kevin R10b5-1

    Executive Chair · Director

    −$1.9M

    May 21, 2026

    26,759 sh · $72.00

  • Brown Michael Jon10b5-1

    EVP, Chief Legal Officer

    −$101.8K

    May 15, 2026

    1,700 sh · $59.91

  • Heller Bridgette P10b5-1

    Director

    −$60.7K

    May 12, 2026

    1,012 sh · $60.01

  • Brown Michael Jon10b5-1

    EVP, Chief Legal Officer

    −$107.2K

    Apr 15, 2026

    1,700 sh · $63.04

  • Brown Michael Jon10b5-1

    EVP, Chief Legal Officer

    −$110.2K

    Mar 16, 2026

    1,700 sh · $64.85

  • Heller Bridgette P10b5-1

    Director

    −$68.8K

    Feb 12, 2026

    1,012 sh · $68.01

  • Collins Richard Alexander10b5-1

    Director

    −$171.6K

    Nov 14, 2025

    2,906 sh · $59.05

  • Heller Bridgette P10b5-1

    Director

    −$58.8K

    Nov 12, 2025

    1,012 sh · $58.07

  • Leach Jacob Steven

    President & COO

    +$863.2K

    Nov 10, 2025

    15,700 sh · $54.98

  • Collins Richard Alexander10b5-1

    Director

    −$217.8K

    Nov 10, 2025

    3,948 sh · $55.17

  • Leach Jacob Steven

    President & COO

    +$138.6K

    Nov 10, 2025

    2,500 sh · $55.43

  • Malady Kyle10b5-1

    Director

    −$53.9K

    Sep 05, 2025

    667 sh · $80.86

  • Stern Sadie10b5-1

    EVP, Chief HR Officer

    −$117.3K

    Sep 04, 2025

    1,466 sh · $80.00

  • Sylvain Jereme M10b5-1

    EVP, Chief Financal Officer

    −$357.8K

    Sep 02, 2025

    4,824 sh · $74.17

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

DexCom, Inc. company record

SEC industry classification
Surgical & Medical Instruments & Apparatus
Headquarters
San Diego, CA
Incorporated in
DE
Listed on
Nasdaq
SEC Central Index Key
0001093557

Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.

After insiders bought DXCM

What the stock actually did in the 90 days following each open-market purchase

Don't check DXCM — let it ping you

Get told the moment an insider moves on DXCM

Pro watches DexCom, Inc. for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add DXCM to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.

Track DXCM on the live dashboardFilings on SEC.gov

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

How to read DXCM insider activity

Open-market purchase (code P)
An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
Grants and option exercises (codes A, M)
Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
Cluster buy
Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Other Health Care tickers

ALGNEWBAXZBHHOLXVTRSMCKCORPODDNBIXSRPTALNY
This week on the tape: who actually chose to sellThe weekly split of scheduled 10b5-1 selling vs deliberate sales, with the deciders named.

Questions

Are DXCM insiders buying or selling?
Between Jun 03, 2026 and Sep 15, 2026, 8 DexCom, Inc. insiders made no open-market purchases and 20 sales worth $9.6M, a net sale of $9.6M. 20 of the sales were pre-scheduled under a Rule 10b5-1 plan.
How much DXCM stock have insiders bought and sold in the last two years?
Between Jul 01, 2024 and Jun 30, 2026, 12 DexCom, Inc. insiders made 2 open-market purchases worth $1M and 57 sales worth $18.5M. 40 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: 2 purchases ($1M) and 24 sales ($5.2M). The largest purchase was Leach Jacob Steven buying $863.2K on Nov 10, 2025. The largest sale was Sayer Kevin R selling $2.9M on Jan 29, 2025.
What was the largest recent DXCM insider trade?
Sayer Kevin R (Executive Chair · Director) sold $2M of DXCM stock on Jul 20, 2026 at about $76.32 a share, under a pre-scheduled 10b5-1 plan.
When did an insider last buy DXCM shares?
No open-market purchase by a DexCom, Inc. insider appears in the filings from Jun 03, 2026 to Sep 15, 2026 — every recorded open-market transaction in that period was a sale. Before that, the most recent purchase in SEC's data was Leach Jacob Steven buying $863.2K on Nov 10, 2025.
Where does DXCM insider trading data come from?
From the Form 4 filings DexCom, Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.

Get the free Insider Brief

Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.

No account needed. One-click unsubscribe.